9 Continued robust sales growth in Syngene (+32%) and recovery in biopharma sales (+9%).Maintainedstrongoperatingperformancedespite78%jumpinR&D;spend 9 ExpectstolaunchGlargineinJapaninH1FY17andregulatoryfilingoffourbiosimilars...